SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (76)2/18/1998 12:21:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 643
 
Bear, Stearns analyst Scott Shevick said Merck was also
helped Tuesday by industry data showing Lilly's Evista
generated only 4,920 new U.S. prescriptions during its fourth
week on drugstore shelves.
He said that figure compared unfavorably with the 10,000
new prescriptions Merck's osteoporosis drug Fosamax generated
during its fourth week on the market in 1995.